Pharsight

Drugs that contain Naloxone Hydrochloride; Oxycodone Hydrochloride

1. Targiniq patents expiration

TARGINIQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(1 year, 28 days from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(1 year, 28 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168252 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9161937 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9345701 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US8969369 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9084729 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9283216 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9056051 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9283221 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US9511066 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(1 year, 9 months ago)

US8846090 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(10 months ago)

US9555000 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(10 months ago)

US9907793 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(10 months ago)

US8846091 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(10 months ago)

Market Authorisation Date: 23 July, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

TARGINIQ family patents

Family Patents